ATLANTA--(BUSINESS WIRE)--Sciele Pharma, Inc. (NASDAQ:SCRX) today announced that it has acquired an innovative head lice asphyxiation product developed by Summers Laboratories, Inc. for the United States, Canada and Mexico. Under the terms of the agreement, Summers will receive an upfront payment, deferred payments upon achievement of certain regulatory milestones including FDA approval of the product and deferred payments based on meeting certain sales targets.
